2019
DOI: 10.1007/s11033-019-05098-7
|View full text |Cite
|
Sign up to set email alerts
|

Encapsulation of crocetin into poly (lactic-co-glycolic acid) nanoparticles overcomes drug resistance in human ovarian cisplatin-resistant carcinoma cell line (A2780-RCIS)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 33 publications
0
8
0
Order By: Relevance
“…In order to explore potential of this compound to treat this kind of tumor in more detail, we reported results regarding in vivo and in vitro models of glioma treated with crocetin. Several authors demonstrated the in vitro antiproliferative action of crocetin in different kinds of tumor cells [29][30][31][32]. In order to evaluate the antiproliferative effect of crocetin on GBM cells, four tumor lines (U251, U87, U138, and U373) were treated with 250 µM and 500 µM of crocetin and counted after 72 h of incubation.…”
Section: Discussionmentioning
confidence: 99%
“…In order to explore potential of this compound to treat this kind of tumor in more detail, we reported results regarding in vivo and in vitro models of glioma treated with crocetin. Several authors demonstrated the in vitro antiproliferative action of crocetin in different kinds of tumor cells [29][30][31][32]. In order to evaluate the antiproliferative effect of crocetin on GBM cells, four tumor lines (U251, U87, U138, and U373) were treated with 250 µM and 500 µM of crocetin and counted after 72 h of incubation.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, it has been determined that it has not toxic effects on L929 healthy cells [ 78 ]. In a study by Neshaburinezad et al [ 80 ] poly (Lactic-co-glycolic acid) -crocetin nanoparticles (PLGA-Crt NP) have been evaluated MRP1 and MRP2 activity in human ovarian cisplatin-resistant carcinoma cell line (A2780-RCIS) and parent form (A2780-RCIS). Encapsulation of crocetin PLGA NPs has enhanced the inhibitory effects on drug resistance by down-regulating MRP2 carriers.…”
Section: Main Textmentioning
confidence: 99%
“…Neyshaburinezhad et al encapsulated crocetin in poly (lactic-coglycolic acid) nanoparticles (PLGA-Crt NPs) to investigate its resistance to cisplatin-resistant human ovarian carcinoma cell line (A2780-RCIS). The results showed that PLGA-Crt NPs (25, 50, 100, 200 μmol) could reduce the gene expression and efflux function of multidrug resistance protein 2 (MRP2) transporters in cisplatin-resistant A2780-RCIS to inhibit cell resistance (Neyshaburinezhad et al, 2019).…”
Section: Ovarian Cancermentioning
confidence: 99%